title: Reduced cumulative incidence of diabetes but not insulitis following administration of chimeric human IL-15-murine IgG2b in NOD mice.
abstract: BACKGROUND
  It has been recently demonstrated that apoptosis is involved in beta-cell destruction in the NOD mouse model of diabetes. The aim of the present study was to investigate whether IL-15, a cytokine involved in the modulation of the apoptotic process, is capable of modifying the natural history of diabetes and/or insulitis in pre-diabetic NOD mice. The rationale for the use of IL-15-IgG2b recombinant cytokine is related to its long half-life (28 +/- 4 h).
  
  
  METHODS
  At 10 weeks of age, 2 groups of 24 female mice were treated with single or multiple i.p. doses of IL-15-IgG2b respectively. As control, 2 groups of 24 age- and litter-matched female mice were injected intra-peritoneally with single or multiple doses of IgG2b immunoglobulin.
  
  
  RESULTS
  Diabetes incidence at 33 weeks of age was lower in the group of mice treated with multiple doses than in the control group (p = 0.03). The cumulative incidence of diabetes at 33 weeks of age between single-dose treated mice and the control group was similar. No significant differences in the calculated index of insulitis were observed in all treated and control mice.
  
  
  CONCLUSIONS
  We conclude that IL-15-IgG2b reduces the cumulative incidence of diabetes, without affecting the extent and severity of the insulitis process. Considering this and the well-defined anti-apoptotic effects of IL-15, we suggest that the reduction of diabetes incidence could be due to a down-regulation of beta-cell apoptosis.
authors.affiliation: Department of Clinical Sciences, University La Sapienza, Rome, Italy. alberto.signore@uniroma1.it
authors.forename: A
authors.initials: A
authors.lastname: Signore
authors.forename: A
authors.initials: A
authors.lastname: Annovazzi
authors.forename: P
authors.initials: P
authors.lastname: Giacalone
authors.forename: P E
authors.initials: PE
authors.lastname: Beales
authors.forename: M G
authors.initials: MG
authors.lastname: Valorani
authors.forename: A R
authors.initials: AR
authors.lastname: Vestri
authors.forename: G
authors.initials: G
authors.lastname: Ruberti
authors.forename: S
authors.initials: S
authors.lastname: Manfrini
authors.forename: P
authors.initials: P
authors.lastname: Pozzilli
authors.forename: S
authors.initials: S
authors.lastname: Bulfone-Paus
mesh_terms: D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology / Q000517:prevention & control*; D006029:Glycosuria; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D015994:Incidence; D019409:Interleukin-15 / Q000494:pharmacology*; D051379:Mice; D016688:Mice, Inbred NOD; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D007074:Immunoglobulin G; D019409:Interleukin-15; D011993:Recombinant Fusion Proteins